Acrivon Therapeutics, Inc. (ACRV) Stock Forecast & Price Target

Compare

669 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACRV Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Acrivon

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACRV Stock 12 Month Forecast

Average Price Target

$10.60

▲(356.90% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Acrivon Therapeutics, Inc. in the last 3 months. The average price target is $10.60 with a high forecast of $19.00 and a low forecast of $6.00. The average price target represents a 356.90% change from the last price of $2.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","15":"$15","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5,10,15,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.99,3.2984615384615386,4.606923076923077,5.915384615384616,7.2238461538461545,8.532307692307693,9.840769230769231,11.14923076923077,12.457692307692309,13.766153846153847,15.074615384615386,16.383076923076924,17.69153846153846,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.99,2.6523076923076925,3.3146153846153847,3.976923076923077,4.639230769230769,5.3015384615384615,5.963846153846154,6.626153846153846,7.288461538461538,7.950769230769231,8.613076923076923,9.275384615384615,9.937692307692307,{"y":10.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.99,2.2984615384615386,2.606923076923077,2.9153846153846152,3.2238461538461536,3.5323076923076924,3.8407692307692307,4.149230769230769,4.457692307692308,4.766153846153846,5.0746153846153845,5.383076923076923,5.691538461538461,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.72,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$10.60

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Bodnar

H.C. Wainwright

$19

Buy

718.97%

Upside

Reiterated

11/25/25

Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial DevelopmentsValuation and Risks. Our Buy rating and $19 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2038 and assign a 12% discount rate and 0% terminal value, which is in-line with other companies in our coverage with platform technologies. We currently assume value for ACR-368 for OncoSignature positive 2L endometrial cancer, with a 45% 2L ovarian cancer with a 20% POS, and have not included other pipeline assets or indications in our valuation.

Matthew Biegler

Oppenheimer

Buy

244.83%

Upside

Reiterated

11/14/25

Analysts Conflicted on These Healthcare Names: Acrivon Therapeutics, Inc. (NASDAQ: ACRV) and Bristol-Myers Squibb (NYSE: BMY)

Michael Okunewitch

Maxim Group

$24→$7

Buy

201.72%

Upside

Reiterated

11/14/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NASDAQ: NTLA) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

Edward Tenthoff

Piper Sandler

Buy

158.62%

Upside

Reiterated

11/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: TELA Bio (NASDAQ: TELA), Candel Therapeutics (NASDAQ: CADL) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

11/13/25

Analysts' Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA)

Silvan Tuerkcan

Citizens JMP

$13

Buy

460.34%

Upside

Reiterated

09/17/25

Citizens JMP Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)

Soumit Roy

JonesTrading

―

Hold

―

Reiterated

08/15/25

JonesTrading Remains a Hold on Acrivon Therapeutics, Inc. (ACRV)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

05/15/25

Cantor Fitzgerald reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Acrivon Therapeutics Inc (NASDAQ: ACRV).

Roger Song

Jefferies

$18

Buy

675.86%

Upside

Assigned

03/26/25

Analysts Are Bullish on These Healthcare Stocks: Phreesia (PHR), Acrivon Therapeutics, Inc. (ACRV)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Bodnar

H.C. Wainwright

$19

Buy

718.97%

Upside

Reiterated

11/25/25

Matthew Biegler

Oppenheimer

Buy

244.83%

Upside

Reiterated

11/14/25

Analysts Conflicted on These Healthcare Names: Acrivon Therapeutics, Inc. (NASDAQ: ACRV) and Bristol-Myers Squibb (NYSE: BMY)

Michael Okunewitch

Maxim Group

$24→$7

Buy

201.72%

Upside

Reiterated

11/14/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NASDAQ: NTLA) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

Edward Tenthoff

Piper Sandler

Buy

158.62%

Upside

Reiterated

11/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: TELA Bio (NASDAQ: TELA), Candel Therapeutics (NASDAQ: CADL) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

11/13/25

Analysts' Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA)

Silvan Tuerkcan

Citizens JMP

$13

Buy

460.34%

Upside

Reiterated

09/17/25

Citizens JMP Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)

Soumit Roy

JonesTrading

―

Hold

―

Reiterated

08/15/25

JonesTrading Remains a Hold on Acrivon Therapeutics, Inc. (ACRV)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

05/15/25

Cantor Fitzgerald reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Acrivon Therapeutics Inc (NASDAQ: ACRV).

Roger Song

Jefferies

$18

Buy

675.86%

Upside

Assigned

03/26/25

Analysts Are Bullish on These Healthcare Stocks: Phreesia (PHR), Acrivon Therapeutics, Inc. (ACRV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Acrivon Therapeutics, Inc.

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+0.05%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +0.05% per trade.

3 Months

xxx

Success Rate

5/11 ratings generated profit

Average Return

+0.77%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +0.77% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

5/10 ratings generated profit

Average Return

-3.54%

reiterated a buy rating 14 days ago

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -3.54% per trade.

2 Years

xxx

Success Rate

4/10 ratings generated profit

Average Return

-22.30%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -22.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACRV Analyst Recommendation Trends

Rating

Apr 25

May 25

Aug 25

Sep 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACRV has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ACRV average Analyst price target in the past 3 months is 10.60.

Each month's total comprises the sum of three months' worth of ratings.

ACRV Financial Forecast

ACRV Earnings Forecast

Next quarter’s earnings estimate for ACRV is -$0.49 with a range of -$0.62 to -$0.38. The previous quarter’s EPS was -$0.47. ACRV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ACRV has Performed in-line its overall industry.

No data currently available

ACRV Sales Forecast

Next quarter’s sales forecast for ACRV is $194.00K with a range of $0.00 to $1.16M. The previous quarter’s sales results were $0.00. ACRV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ACRV has Performed in-line its overall industry.

ACRV Stock Forecast FAQ

What is ACRV’s average 12-month price target, according to analysts?

Based on analyst ratings, Acrivon Therapeutics, Inc.’s 12-month average price target is 10.60.

What is ACRV’s upside potential, based on the analysts’ average price target?

Acrivon Therapeutics, Inc. has 356.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACRV a Buy, Sell or Hold?

Acrivon Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Acrivon Therapeutics, Inc.’s price target?

The average price target for Acrivon Therapeutics, Inc. is 10.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $6.00. The average price target represents 356.90% Increase from the current price of $2.32.

What do analysts say about Acrivon Therapeutics, Inc.?

Acrivon Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ACRV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Acrivon Therapeutics, Inc. (ACRV) Stock Forecast & Price Target

ACRV Analyst Ratings

ACRV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Acrivon Therapeutics, Inc.

ACRV Analyst Recommendation Trends

ACRV Financial Forecast

ACRV Earnings Forecast

ACRV Sales Forecast

ACRV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts